Evofosfamide(TH-302)可增敏食管癌放疗而不增加正常组织毒性
本研究在食管鳞癌(OE21)与腺癌(OE19)移植瘤模型中,评估低氧激活前药evofosfamide(TH-302)联合放疗的疗效,并在肠道黏膜与肺纤维化模型中评估正常组织毒性。结果显示TH-302联合放疗较单纯放疗显著延迟肿瘤生长,且未加重放疗引起的短期肠道与长期肺毒性。
要点
- TH-302联合放疗较单纯放疗显著延迟OE19与OE21食管癌移植瘤生长。
- TH-302未加重放疗所致肠道黏膜短期损伤与肺纤维化长期毒性。
- TH-302联合放疗可能改善食管癌治疗指数。
核心结论
- TH-302联合放疗可能通过增敏食管癌而不增加正常组织毒性来改善治疗指数。
研究设计与样本
- 采用OE21食管鳞癌与OE19食管腺癌移植瘤模型评估TH-302(50 mg/kg,QD5)联合照射(假照射或10 Gy)的疗效。
- 采用肠道黏膜与肺纤维化照射模型评估短期与长期毒性,小鼠注射TH-302(50 mg/kg,QD5)后腹部照射(假照射、8或10 Gy)或右肺上部照射(假照射、20 Gy)。
主要发现
- TH-302联合放疗较单纯放疗显著延迟OE19(P = 0.02)与OE21(P = 0.03)肿瘤生长。
- 照射导致隐窝存活、黏膜表面积与瓜氨酸水平呈剂量依赖性下降(分别P < 0.001、P < 0.01、P < 0.001)。
- 长期照射增加肺CT密度提示纤维化,TH-302未影响放疗诱导的短期与长期毒性。
临床怎么用
- 结果支持在食管癌中进一步研究TH-302联合放疗的临床转化潜力。
局限性
- 证据来自移植瘤与正常组织照射模型,尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Esophageal cancer incidence is increasing and is rarely curable. Hypoxic tumor areas cause resistance to conventional therapies, making them susceptible for treatment with hypoxia-activated prodrugs (HAPs). We investigated in vivo whether the HAP evofosfamide (TH-302) could increase the therapeutic ratio by sensitizing esophageal carcinomas to radiotherapy without increasing normal tissue toxicity. MATERIALS AND METHODS: To assess therapeutic efficacy, growth of xenografted esophageal squamous cell (OE21) or adeno (OE19) carcinomas was monitored after treatment with TH-302 (50 mg/kg, QD5) and irradiation (sham or 10 Gy). Short- and long-term toxicity was assessed in a gut mucosa and lung fibrosis irradiation model, sensitive to acute and late radiation injury respectively. Mice were injected with TH-302 (50 mg/kg, QD5) and the abdominal area (sham, 8 or 10 Gy) or the upper part of the right lung (sham, 20 Gy) was irradiated. Damage to normal tissues was assessed 84 hours later by histology and blood plasma citrulline levels (gut) and for up to 1 year by non-invasive micro CT imaging (lung). RESULTS: The combination treatment of TH-302 with radiotherapy resulted in significant tumor growth delay in OE19 (P = 0.02) and OE21 (P = 0.03) carcinomas, compared to radiotherapy only. Irradiation resulted in a dose-dependent decrease of crypt survival (P < 0.001), mucosal surface area (P < 0.01) and citrulline levels (P < 0.001) in both tumor and non-tumor bearing animals. On the long-term, irradiation increased CT density in the lung, indicating fibrosis, over time. TH-302 did not influence the radiation-induced short-term and long-term toxicity, confirmed by histological evaluation. CONCLUSION: The combination of TH-302 and radiotherapy might be a promising approach to improve the therapeutic index for esophageal cancer patients.
引用
- Spiegelberg L, van Hoof SJ, Biemans R, et al. Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. Radiother Oncol. 2019. PMID: 31431383. doi:10.1016/j.radonc.2019.06.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。